Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice

Biological Chemistry

Volumn 395, Issue 4, 2014, Pages 453-464

  Moran, Brian M ^a   Abdel Wahab, Yasser H A ^a   Flatt, Peter R ^a   McKillop, Aine M ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

GPR119; insulin secretion; lipid agonists; pancreatic islets; type 2 diabetes

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; AS 1269574; CALCIUM; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; GLUCOSE; INSULIN; LACTATE DEHYDROGENASE; N OLEOYLETHANOLAMINE; PALMIDROL; PSN 375963; UNCLASSIFIED DRUG; 2-(2-(4-BROMOPHENYL)-6-METHYLPYRIMIDIN-4-YL)AMINOETHANOL; ETHANOLAMINE DERIVATIVE; FATTY ACID; GPR119 PROTEIN, MOUSE; OLEIC ACID; OXADIAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CELL ISOLATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; GLUCOSE TOLERANCE; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREATIC POLYPEPTIDE SECRETING CELL; PRIORITY JOURNAL; STIMULUS SECRETION COUPLING; AGONISTS; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; METABOLISM; SECRETION (PROCESS); STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FATTY ACIDS; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN-SECRETING CELLS; MICE; OLEIC ACIDS; OXADIAZOLES; PYRIDONES; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896799177     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2013-0255     Document Type: Article

References (33)

1. Bailey, C.J. and Flatt, P.R. (1982). Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obesity 6, 11-21. (Pubitemid 12157286)
2. Chu, Z.L., Jones, R.M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M., Gao, H., Mondala, H., Bagnol, D., et al. (2007). A role for β-cell-expressed G protein-coupled receptor 119 in glycaemic control by enhancing glucose-dependent insulin release. Endocrinology 148, 2601-2609. (Pubitemid 46984798)
3. Chu, Z., Carroll, C., Alfonso, J., Gutierrez, V., He, H., Lucman, A., Pedraza, M., Mondala, H., Gao, H., Bagnol, D., et al. (2008). A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycaemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149, 2038-2047. (Pubitemid 351574507)
4. Cox, H.M., Tough, I.R., Woolston, A.M., Zhang, L., Nguyen, A.M., Sainsbury, A. and Herzog, H. (2010). Peptide YY is critical for acylethanolamide receptor GPR119-induced activation of gastrointestinal mucosal responses. Cell Metab. 11, 532-542.
5. Flatt, P.R. and Bailey, C.J. (1981). Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20, 573-577. (Pubitemid 11096955)
6. Flock, G., Holland, D., Seino, Y. and Drucker, D.J. (2011). GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 152, 374-383.
7. Fyfe, M.T.C., McCormack, J.G., Overton, H.A., Procter, M.J. and Reynet, C. (2008). GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity. Expert Opin. Drug Discov. 3, 403-413. (Pubitemid 351618767)
8. Godlewski, G., Offertaler, L., Wagner, J.A. and Kunos, G. (2009). Receptors for acylethanolamides-GPR55 and GPR119. Prosta-glandins Other Lipid Mediat. 89, 105-111.
9. Hansen, K.B., Rosenkilde, M.M., Knop, F.K., Wellner, N., Diep, T.A., Rehfeld, J.F., Anderson, J.B., Holst, J.J., and Hansen, H.S. (2011). 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J. Clin. Endocrinol. Metab. 96, E1409-E1417.
10. Katz, L.B., Gamable, J.J., Rothenberg, P.L., Vanapalli, S.R., Vaccaro, N., Xi, L., Polidori, D.C., Vets, E., Sarich, T.C., and Stein, P.P. (2011). Pharmacokinetics, Pharmacodynamics, safety and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. Clin. Pharmacol. Ther. 90, 685-692.
11. Katz, L.B., Gambale, J.J., Rothenberg, P.L., Vanapalli, S.R., Vaccaro, N., Xi, L., Sarich, T.C., and Stein, P. P. (2012). Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomised, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes. Metab. 14, 709-716.
12. Kim, W. and Egan, J.M. (2008). The role of incretins in glucose homeostasis and diabetes treatment. Pharmaceut Rev. 60, 470-512.
13. Lan, H., Lin, H.V., Wang, C.F., Wright, M.J., Xu, S., Kang, L., Juhl, K., Hedrick, J.A., and Kowalski, T.J. (2012). Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br. J. Pharmacol. 165, 2799-2807.
14. Lauffer, L.M., Iakoubov, R. and Brubaker, P.L. (2009). GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cells. Diabetes 58, 1058-1066.
15. McClenaghan, N.H., Barnett, C.R., Ah-Sing, E., Abdel-Wahab, Y.H., O'Harte, F.P.M., Yoon, Y.M., Swanston-Flatt, S.K., and Flatt, P.R. (1996). Characterisation of a novel glucose-responsive insulin-secreting cell line, BRIN BD11, produced by electrofusion. Diabetes 45, 1132-1140. (Pubitemid 26260168)
16. Miguel, J.C., Patterson, S., Abdel-Wahab, Y.H.A., Mathias, P.C. and Flatt, P.R. (2004). Time-correlation between membrane depolarization and intracellular calcium in insulin secretion BRIN-BD11 cells: studies using FLIPR. Cell Calcium 36, 43-50. (Pubitemid 38684487)
17. Moskalewski, S. (1969). Studies on the culture and transplantation of isolated islets of langerhans of the guinea pig. Proc. K. Ned. Akad. Wet. 72, 157-171.
18. Ning, Y., O'Neill, K., Lan, H., Pang, L., Shan, L.X., Hawes, B.E., and Hedrick, J.A. (2008). Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br. J. Pharmacol. 155, 1056-1065.
19. Ohishi, T. and Yoshida, S. (2012). The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin. Investig. Drugs 21, 321-328.
20. Overton, H.A., Babbs, A.J., Doel, S.M., Fyfe, M.C.T., Gardner, L.S., Griffin, G., Jackson, H.C., Procter, M.J., Rasamison, C.M., Tang-Christensen, M., et al. (2006). Deorphanisation of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agent. Cell Metab. 3, 167-175.
21. Overton, H.A., Fyfe, M.C.T. and Reynet, C. (2008). GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 153, S76-S71.
22. Parker, H.E., Habib, A.M., Rogers, G.J., Gribble, F.M. and Reimann, F. (2009). Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52, 289-298.
23. Pavon, F.J., Serrano, A., Perez-Valero, V., Jagerovic, N., Hernandez-Folgado, L., Bermudez-Silva, F.J., Macias, M., Goya, P., and de Fonseca, F.R. (2008). Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonism, in Zucker rats. J. Neuroendocrinol. 20, 116-123. (Pubitemid 351552685)
24. Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., Greasley, P.J. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101. (Pubitemid 350166046)
25. Sakamoto, K., Inoue, H., Kawakami, S., Miyawaki, K., Miyamoto, T., Mizuta, K., and Itakura, M. (2006). Expression and distribution of GPR119 in pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem. Biophys. Res. Commun. 351, 474-480. (Pubitemid 44666712)
26. Soga, T., Ohishi, T., Matsui, T., Saito, T., Matsumoto, M., Takasaki, J., Matsumoto, S., Kamohara, M., Hiyama, H., Yoshida, S., et al. (2005). Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 326, 744-751. (Pubitemid 39655983)
27. Stone, V.A., Dhayal, S., Smith, D.M., Lenaghan, C., Brocklehurst, K.G., and Morgan, N.G. (2012). The cytoprotective effects of oleoyl ethanolamide in insulin-secreting cells do not require activation of GPR119. Br. J. Pharmacol. 165, 2758-2770.
28. Swaminath, S. (2008). Fatty acid binding receptors and their physiological role in type 2 diabetes. Arch. Pharm. Chem. Life Sci. 341, 753-761.
29. Thabuis, C., Tissot-Favre, D., Bezelgues, J.B., Martin, J.C., Cruz-Hernandez, C., Dionisi, F., and Destaillats, F. (2008). Biological functions and metabolism of oleoylethanolamide. Lipids 43, 887-894.
30. Winzell, M.S. and Ahren, B. (2007). G-protein-coupled receptors and islet function-Implications for treatment of type 2 diabetes. Pharmacol. Ther. 116, 437-448. (Pubitemid 350116941)
31. Witkamp, R.F. (2011). Current and future drug targets in weight management. Pharmaceut. Res. 28, 1792-1818.
32. Yoshida, S., Tanaka, H., Oshima, H., Yamazaki, T., Yonetoku, T., Ohishi, T., Matsui, T., and Shibasaki, M. (2010a). AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Biochem. Biophys. Res. Commun. 400, 745-751.
33. Yoshida, S., Ohishi, T., Matsui, T. and Shibasaki, M. (2010b). Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem. Biophys. Res. Commun. 400, 437-441.